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Abstract
Background: A specific humoral immune response against HERV-W envelope surface (env-su) gly-
coprotein antigens has been reported in serum of patients with multiple sclerosis (MS). However, it has
not been evaluated to date in patients with neuromyelitis optica spectrum disorder (NMOSD).
Objective: The objective of this paper is to investigate whether antibody (Ab) response against HERV-
W env-su antigenic peptides differs between NMOSD and MS.
Methods: Serum samples were collected from 36 patients with NMOSD, 36 patients with MS and 36
healthy control individuals (HCs). An indirect ELISA was set up to detect specific Abs against HERV-
W env-su peptides.
Results: Our data showed that two antigenic peptides, particularly HERV-Wenv93–108 and HERV-
Wenv248–262, were statistically significantly present only in serum of MS compared to NMOSD and
HCs. Thus, the specific humoral immune response against HERV-W env-su glycoprotein antigens found
in MS is widely missing in NMOSD.
Conclusion: Increased circulating serum levels of these HERV-W Abs may be suitable as additional
biomarkers to better differentiate MS from NMOSD.
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Introduction
Multiple sclerosis (MS) is the most common chronic
inflammatory demyelinating disease of the central
nervous system (CNS) with an unclear immune-
mediated pathogenesis. Several data support the
hypothesis of a possible infectious stimulus as a trig-
ger of the pathogenic cascade.1–3 Given the lack of
specific biomarkers, MS diagnosis is generally
accomplished if precise clinical and neuroimaging
criteria are satisfied and any other diagnostic possi-
bilities have been excluded.4,5 Nevertheless, around
5%–10% of MS diagnoses have to be reconsidered
after two years.6,7 Neuromyelitis optica (NMO) has
been considered for many years a more severe var-
iant of MS, mainly involving the spinal cord and
optic nerves. However, the discovery of a specific
antibody (Ab) directed against aquaporin-4 (AQP4-
immunoglobulin (Ig)G), the main channel protein
that facilitates the transport of water at the astroglial
cell level in the CNS, has conferred to the pathology
an identity different from MS.8 At present, the term
NMO spectrum disorders (NMOSD) also includes
patients with AQP4-IgG positivity and signs/symp-
toms related to involvement of CNS regions other
than the spinal cord and optic nerves, such as brain-
stem, diencephalon and subcortical white matter.9,10
Moreover, a variant AQP4-negative is known, which
can be diagnosed when definite clinical and neuro-
imaging criteria specific for NMOSD are satisfied.9
These “seronegative” forms represent approximately
12% and are likely due to the known fluctuations in
the serum autoantibody titer below the identification
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threshold. Interestingly, anti-myelin oligodendrocyte
glycoprotein Abs (MOG-IgG) have been detected in
10%–15% of the seronegative NMOSD forms, sug-
gesting that different autoantigens other than AQP4
may play a role in this disorder.11
Currently, NMOSD remains the main differential
diagnosis for MS. Thus, the identification of bio-
humoral markers able to differentiate between
NMOSD and MS is highly desirable for improving
diagnosis and selecting the most appropriate and
effective treatment.
Recent studies have shown that the expression of
human endogenous retrovirus of the W family
(HERV-W) could play a role in MS pathogene-
sis.12–16 In particular, HERV-W env proteins’ effects
in MS may involve the activation of innate immune
pathways and facilitate an abnormal pro-
inflammatory and super-antigenic immune
response.17–19 Moreover, serum Abs directed against
the glycoprotein encoded by this retrovirus may be
useful, in clinical practice, as serum biomarkers
indicative of MS.20 Given these findings, we studied
the role of Ab response against HERV-W envelope
surface (env-su) peptides in NMOSD. In this paper,
we document for the first time a different serum
humoral immune response against immunogenic
peptides derived from HERV-W env proteins
between MS and NMOSD patients.
Materials and methods
Participants
The study protocol was approved by the local ethics
committee (Prot. 2457/2017, Azienda Sanitaria
Locale 1, Sassari, Italy). Among patients referred
for serum AQP4/MOG-IgG analysis to the
Laboratory of Neuropathology, University Hospital
of Verona, Italy, we identified those eventually diag-
nosed with NMOSD. All patients consented to diag-
nostic procedures and biological sample storage at
Verona Neuropathology Laboratory. Patients within
one year of MS onset were enrolled at the Neurology
Clinic of the University Hospital of Sassari. Age-
and sex-matched healthy control individuals (HCs)
were recruited at the Blood Transfusion Centre of
Sassari. Peripheral venous blood of patients and HC
donors was collected. All the participants provided
written informed consent. Patients who underwent
immunomodulatory/immunosuppressive therapy
during the 12-month period prior to blood sampling
were excluded. The diagnosis of MS and NMOSD
was based on the established criteria.4,9
The cohort included 36 MS patients (27 females and
nine males; mean ageSD, 45.5 8.0 years)
diagnosed with relapsing–remitting MS (RRMS),
who presented with at least two cerebrospinal fluid
(CSF)-restricted oligoclonal bands, 36 NMOSD
patients (31 females and five males; mean age
SD, 51.1 16.8 years) and 36 HCs. Sera of
NMOSD patients were tested at the Laboratory of
Neuropathology, University Hospital of Verona,
Italy, for Abs to AQP4 using a commercially avail-
able cell-based assay (CBA) (Anti-Aquaporin-4
IIFT, Euroimmun, Lu¨beck, Germany), and for
MOG-IgG using recombinant live cell-based immu-
nofluorescence assay with HEK293A cells trans-
fected with full-length MOG, as previously
described.21
Peptides
In silico analysis performed by IETB Analysis
Resource software allowed us to identify several anti-
genic peptides derived from HERV-W env protein
(UniProtKB accession number: Q9UQF0): HERV-
W env93–108 (NPSCPGGLGVTVCWTY), HERV-W
env129–143 (VKEVISQLTRVHGTS), HERV-W
env161–180 (HTRLVSLFNTTLTGLHEVSA), and
HERV-W env248–262 (NSQCIRWVTPPTQIV)
belonging to the surface region of the protein. All
peptides were synthesized commercially (LifeTein,
South Plainfield, NJ 07080, USA) with a
purity> 90% and kept frozen in single-use aliquots
(10 mM) at 80C.
Enzyme-linked immunosorbent assay (ELISA)
method
Indirect ELISA was carried out to detect specific
antibodies (Abs) against HERV-W env peptides
(assayed at 10 mg/ml). Ninety-six-well Nunc immu-
noplates were coated overnight at 4C with 10 mg/ml
of peptides diluted in 0.05 M carbonate-bicarbonate
buffer, pH 9.5 (Sigma). Plates were then blocked for
one hour at room temperature with 5% non-fat dried
milk (Sigma) and washed twice with phosphate-
buffered saline (PBS) containing 0.05% Tween-20
(PBS-T). Sera samples were subsequently added at
1:100 dilution in PBS-T for two hours at room tem-
perature. After five washes in PBS-T, 100 ml of alka-
line phosphatase-conjugated goat anti-human IgG
polyclonal Ab (1:1000; Sigma) was added for
one hour at room temperature. Plates were washed
again five times in PBS-T and para nitrophenylphos-
phate (Sigma) added as substrate for alkaline phos-
phatase. Plates were incubated at 37C in the dark
for three to six minutes and the absorbance at
405 nm read on a VERSATunable Max microplate
reader (Molecular Devices). Negative control wells
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were obtained by incubation of immobilized
peptides with secondary Ab alone, and their mean
values subtracted from all samples. Positive control
sera were also included in all experiments. Results
are expressed as means of triplicate 405 nm optical
density (OD) values.
Statistical analysis
The analysis was carried out using GraphPad Prism
6.0 software (San Diego, CA, USA). Continuous
variables were presented as mean standard devia-
tion (SD), and categorical variables as numbers and
percentages. Kruskal-Wallis multiple comparison
test was performed as post hoc for multiple compar-
isons, the Mann-Whitney U test was used to com-
pare two groups, and a value of p< 0.05 was
considered significant. The diagnostic value of the
indirect ELISA assays was evaluated by the receiver
operating characteristic (ROC) curve. The optimal
cut-off values were chosen according to ROC anal-
ysis, setting specificity and sensitivity at 90% for all
serum samples measured.
Results
Abs against HERV-W env peptides were evaluated
in serum of patients from the three groups (Figure 1).
Abs against HERV-W env-su93–108 were found in
the sera of 28 out of 36 (78%) MS patients and 17
out of 36 (47%) HCs whereas only three out of 36
(8%) NMOSD were positive (AUC¼ 0.85, HC vs
MS vs NMOSD, p< 0.0001, MS vs NMOSD,
p< 0.0001) (Figure 1(a)). Regarding the HERV-W
env-su129–143, 15 out of 36 (42%) MS patients, 23
out of 36 (64%) HCs, and five out of 36 (14%)
among NMOSD patients were positive in serum
(AUC¼ 0.5, HCs vs MS vs NMOSD, p¼ 0.009)
(Figure 1(b)). Concerning HERV-W env-su161–180,
no statistical differences were found regarding pos-
itivity against this peptide that was recognized by 23
out of 36 (64%) HCs, by 17 out of 36 (47%) MS
patients, and by 17 out of 36 (47%) NMOSD
patients (AUC¼ 0.5, p¼NS) (Figure 1(c)). Serum
reactivity against HERV-W env-su248–262 peptide
was found in 23 out of 36 (64%) MS patients; how-
ever, only seven out of 36 (19%) NMOSD were
positive, whereas none of the HCs was positive
(AUC¼ 0.76, HCs vs MS vs NMOSD, p< 0.0001,
MS vs NMOSD, p¼ 0.0001) (Figure 1(d)).
Among NMOSD patients, 25 were seropositive for
AQP4-IgG and 11 were seronegative. All of them
were seronegative for MOG-IgG. Only one of the
AQP4-IgG–negative NMOSD patients showed Abs
against HERV-W env-su93–108 and HERV-W
Figure 1. Prevalence of antibodies against peptides derived from human endogenous retrovirus of the W family
(HERV-W) envelope protein in serum. Thirty-six neuromyelitis optica spectrum disorder (NMOSD) patients, 36 with
multiple sclerosis (MS) and 36 healthy controls (HCs) were screened for immunoglobulin G antibodies by indirect
enzyme-linked immunosorbent assay against HERV-Wenv93–108 (a), HERV-Wenv129–143 (b), HERV-Wenv161–180 (c)
and HERV-Wenv248–262 (d) peptides. Scatter plots present median values with interquartile range. Area under receiver
operating characteristic curve (AUC) as well as p values are displayed.
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env-su248–262. Furthermore, NMOSD patients were
divided by age (50 or >50). Fourteen out of 16
(87.5%) patients showed positivity toward AQP4
antibodies and were more than 50 years of age,
while 11 out 20 (55%) patients were younger than
50 years of age and showed positivity toward AQP4
antibodies. No difference has been observed regard-
ing Ab positivity against HERV-W env-su248–262
peptide with respect to age.
Discussion
This study is the first to evaluate the humoral
response against selected peptides of HERV-W env
proteins in a cohort of patients with NMOSD. The
key result of the study is that NMOSD and RRMS
show a differential Ab reactivity to HERV-W env-su
glycoprotein antigens detectable in serum. Indeed,
none of the peptides evaluated was significantly rec-
ognized by NMOSD patients, regardless of age at
initial symptom onset. Notably, only HERV-W
env-su 93–108 and HERV-W env-su248–262 were
able to show a significant immune response in MS
patients when compared to HCs, as previously
observed by Mameli et al.20
Interestingly, although our data are in line with the
previous study by Mameli et al., in this study we
found a significantly higher percentage of MS
patients with specific Ab titers (31.25% vs 78%
and 15% vs 64% for HERV-W env-su93–108 and
HERV-W env-su248–262, respectively). This differ-
ence may be due, at least in part, to the more het-
erogeneous cohort studied by Mameli et al., which
also included both primary and secondary progres-
sive MS patients. Moreover, all of our patients with
RRMS presented with CSF-restricted oligoclonal
bands, which, although no longer required for MS
diagnosis,4 are useful for characterization of a homo-
geneous sample of patients. In our study, Ab
response against HERV-W env-su93–108 was able
to better discriminate between MS and NMOSD
(78% vs 8%, p< 0.0001), although this response
was also observed in a significant proportion of
HCs (47%). Why NMOSD patients have a lower
prevalence of these HERV-W antibodies compared
to HCs is unclear. Previous studies might support the
hypothesis that these autoantibodies (in HCs) may
also serve a protective function.22 By contrast, no
response against HERV-W env-su248–262 was
observed in HCs (0%). Of note, this response was
statistically significantly different between MS and
NMOSD patients also (64% vs 19%, p¼ 0.0001).
Moreover, none but one of the 11 AQP4-IgG-
negative NMOSD patients expressed antibodies
against HERV-W env-su93–108 and HERV-W env-
su248–262. This finding further supports the useful-
ness of the Wingerchuck criteria for distinguishing
AQP4-IgG-seronegative NMOSD from MS.9
Thus, the present data suggest that two of the four
selected HERV-W peptides can discriminate
between MS and NMOSD. The fact that they pro-
vide significantly decreased Ab reactivity in
NMOSD, while discriminating an increased Ab
response in MS vs HCs (HERV-Wenv-su93–108), is
by itself indicative that this could be a useful bio-
marker for a differential diagnosis. Moreover, with
examples of AQP4-negative cases, this decreased
Ab reactivity could reveal complementary to
AQP4-IgG detection for NMOSD diagnosis when
the latter is negative. The same data may also sug-
gest that, if MS may be associated with HERV-W
pathogenic expression, NMOSD would not be.
Nonetheless, immunoreactivity to peptides
Wenv248–262 also shows that a significant Ab
response can be detected in NMOSD. Thus,
HERV-W may also be associated with a subgroup
of NMOSD patients for whom known bioclinical
parameters could be compared to “negative”
others. As Ab responses vary in time, this may con-
versely reflect physiopathological variations without
relation to particular clinical subtype. Regardless, a
major question arises since the Ab response to given
epitopes from an antigenic protein is driven by indi-
vidual major histocompatibility complex (MHC)
class II phenotypes. Thus, considering a global
involvement of HERV-W, the “negative” response
to the two peptides and the lower response to a third
one, when compared to MS, may reflect different
human leukocyte antigen (HLA)-DR/DQ pheno-
types between MS and NMOSD patients. Future
studies will clarify the eventual contribution of
MHC in this differential reactivity to different
selected antigenic peptides/epitopes.
This is a pilot study with some limitations, in par-
ticular the lack of follow-up and the relatively small
sample size (also considering the relative rarity of
NMOSD). Furthermore, we have not evaluated Ab
response in CSF because it was not available for all
NMOSD patients. The MS patients of this study
were not routinely tested for AQP4-IgG and MOG-
IgG at the time of diagnosis. However, all MS
patients included in the study presented with CSF-
restricted oligoclonal bands that are commonly
absent both in NMOSD- and MOG-IgG–positive
patients, thus reducing the possibility of
misdiagnosis.
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In conclusion, our results show that the humoral Ab
response against HERV-W env peptides may be a
potential valuable biomarker in differentiating two
chronic inflammatory demyelinating diseases of the
CNS such as NMOSD and RRMS, especially in
patients in whom AQP4 antibodies are not detect-
able. Similarly, the study of human endogenous ret-
roviruses in NMOSD and other autoimmune non-
MS demyelinating conditions of the CNS may help
to better understand the controversial role of these
HERVs in MS pathogenesis. For this purpose,
MOG-IgG are emerging as useful in clinical practice
in delineating a distinct autoimmune oligodendro-
cytopathy different from MS.22-24
Future research is needed to reproduce these results
in different cohorts including MOG-IgG–positive
patients and those with other non-MS demyelinating
disorders, in order to clarify if the Ab response
against HERV-W env antigenic peptides may be
used as a useful biomarker for MS in clinical
practice.
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